Quest Diagnostics (DGX) Stock Price, News & Analysis

Company Overview

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Key Stats

• Today's Range: $171.36 to $173.42
• 50-Day Range: $160.03 to $178.92
• 52-Week Range: $135.47 to $179.99
• Volume: 1.61 million shs
• Average Volume: 994,037 shs
• Market Capitalization: $19.32 billion
• P/E Ratio: 22.51
• Dividend Yield: 1.85%
• Price Target: $185.73
• Consensus Rating: Moderate Buy

Quest Diagnostics Stock Analysis - MarketRank™

Quest Diagnostics scored higher than 98% of companies evaluated by MarketBeat, and ranked 21st out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Quest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Quest Diagnostics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.14%

Earnings Growth

Earnings for Quest Diagnostics are expected to grow by 8.14% in the coming year, from $9.70 to $10.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quest Diagnostics is 22.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.25.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quest Diagnostics is 22.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.00.

Price to Earnings Growth Ratio

Quest Diagnostics has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Quest Diagnostics has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.51% of the float of Quest Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Quest Diagnostics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quest Diagnostics has recently decreased by 2.74%, indicating that investor sentiment is improving.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Quest Diagnostics pays a meaningful dividend of 1.84%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Quest Diagnostics has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Quest Diagnostics is 40.46%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 30.51% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.62

Percentage of Shares Shorted

3.51% of the float of Quest Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Quest Diagnostics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quest Diagnostics has recently decreased by 2.74%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.02

News Sentiment

Quest Diagnostics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Quest Diagnostics this week, compared to 15 articles on an average week.

Search Interest

Only 3 people have searched for DGX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,914,433.00 in company stock.

Percentage Held by Insiders

Only 8.16% of the stock of Quest Diagnostics is held by insiders.

Percentage Held by Institutions

88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DGX Stock Analysis - Frequently Asked Questions

How have DGX shares performed this year?

Quest Diagnostics' stock was trading at $150.86 at the beginning of 2025. Since then, DGX shares have increased by 14.7% and is now trading at $173.07.
View the best growth stocks for 2025 here.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) posted its earnings results on Tuesday, April, 22nd. The medical research company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.06. The medical research company had revenue of $2.65 billion for the quarter, compared to analysts' expectations of $2.63 billion. Quest Diagnostics had a net margin of 8.80% and a trailing twelve-month return on equity of 15.07%.
Read the conference call transcript.

Does Quest Diagnostics have any subsidiaries?

The following companies are subsidiaries of Quest Diagnostics: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more.

When did Quest Diagnostics IPO?

Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at a price of $4.00-$6.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO.

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' top institutional investors include Vanguard Group Inc. (12.48%), Price T Rowe Associates Inc. MD (5.36%), Victory Capital Management Inc. (2.81%) and Davis Selected Advisers (2.14%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Timothy M Ring, Vicky B Gregg, Karthik Kuppusamy and Mark E Delaney.
View institutional ownership trends.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Record date for 4/21 Dividend: 4/07/2025
• Ex-Dividend for 4/21 Dividend: 4/07/2025
• Dividend Payable: 4/21/2025
• Last Earnings: 4/22/2025
• Today: 5/31/2025
• Record date for 7/21 Dividend: 7/07/2025
• Ex-Dividend for 7/21 Dividend: 7/07/2025
• Dividend Payable: 7/21/2025
• Next Earnings (Estimated): 7/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:DGX
• CIK: 1022079
• Web: www.questdiagnostics.com
• Phone: (973) 520-2700
• Fax: 201-462-4169
• Employees: 49,000
• Year Founded: 1967

Price Target and Rating

• Average Stock Price Target: $185.73
• High Stock Price Target: $200.00
• Low Stock Price Target: $170.00
• Potential Upside/Downside: +7.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $7.91
• Trailing P/E Ratio: 22.51
• Forward P/E Ratio: 17.84
• P/E Growth: 2.16
• Net Income: $871 million
• Net Margins: 8.80%
• Pretax Margin: 11.90%
• Return on Equity: 15.07%
• Return on Assets: 6.72%

Debt

• Debt-to-Equity Ratio: 0.82
• Current Ratio: 1.10
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: $10.16 billion
• Price / Sales: 1.90
• Cash Flow: $13.50 per share
• Price / Cash Flow: 12.82
• Book Value: $61.04 per share
• Price / Book: 2.84

Miscellaneous

• Outstanding Shares: 111,635,000
• Free Float: 110,733,000
• Market Cap: $19.32 billion
• Optionable: Optionable
• Beta: 0.52